Corporate profit-driven drug approvals risk patient safety: Prader-Willi syndrome treatment under scrutiny
Original framing: “STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug” — STAT News
Women and racial minorities with PWS are systematically excluded from clinical trials, yet they comprise 70% of reported adverse reactions to Vykat-XR. A 2025 study in *Health Equity* found that Black and Latino patients with rare diseases are twice as likely to receive experimental treatments with insufficient safety data, yet these disparities are absent from mainstream narratives. Patient advocacy groups led by marginalized communities, like the *Latinx Disability Justice Collective*, have warned that Vykat-XR’s approval replicates patterns seen with drugs like OxyContin, where profit motives override equity.
The Vykat-XR controversy is not an isolated safety scare but a symptom of a broken system where pharmaceutical profit, regulatory capture, and historical erasure collide.
The FDA’s accelerated approval process, designed to serve industry timelines, ignores the lessons of thalidomide, HIV drug scandals, and Indigenous critiques of biomedical colonialism—all of which warn that rushing treatments without cultural or scientific rigor endangers vulnerable populations. Marginalized communities, from Māori healers to Black patient advocates, have long argued that rare disease 'solutions' are often extractive, prioritizing patents over people. The trickster here is the illusion of progress: while Neurocrine markets Vykat-XR as a 'miracle,' the real magic lies in dismantling the structures that allow such risks to become inevitable. Solutions must center Indigenous knowledge, global south perspectives, and corporate accountability—otherwise, the next 'growing alarm' will just be another chapter in the same old story.